ArticleJournal of personalized medicine2021
EPR-Effect Enhancers Strongly Potentiate Tumor-Targeted Delivery of Nanomedicines to Advanced Cancers: Further Extension to Enhancement of the Therapeutic Effect.
Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- From basic to clinical translation: advances and perspectives of photodynamic nanodrugs.Frontiers in pharmacology · 2025Pooled it
- Rational design of lipid-based nanoparticles for targeted anticancer therapies.Drug delivery and translational research · 2026Review
- Perfluorocarbon nanodroplets are cytocompatible with osteoblast-lineage cells and modulate in vitro osteoclastogenesis differentially in normoxia and hypoxia.Scientific reports · 2026Article
- Delivery of lipid nanoparticles containing small interfering RNA targeting transmembrane serine protease 4 in a human gastric cancer model using nude mice.Scientific reports · 2025Article
- TXB-001, A Newly-Developed Polymer-Conjugated Anthracycline, Alleviates Anthracycline-Induced Cardiotoxicity.Cardiovascular toxicology · 2025Article
- An oxygen-generating nanoplatform remodels the immunosuppressive tumor microenvironment via synergistic lactate depletion and sonodynamic therapy.Journal of nanobiotechnology · 2025Article
- Photodynamic Therapy Using IR-783 Liposomes for Advanced Tongue and Breast Cancers in Humans.Journal of functional biomaterials · 2024Article
- Article
- Gold Nanoparticles: Construction for Drug Delivery and Application in Cancer Immunotherapy.Pharmaceutics · 2023Review
- Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis.Journal of personalized medicine · 2023Review
- Research Status and Prospect of Non-Viral Vectors Based on siRNA: A Review.International journal of molecular sciences · 2023Review
- Enhanced Permeability and Retention Effect as a Ubiquitous and Epoch-Making Phenomenon for the Selective Drug Targeting of Solid Tumors.Journal of personalized medicine · 2022Review
- Experience with Photodynamic Therapy Using Indocyanine Green Liposomes for Refractory Cancer.Journal of personalized medicine · 2022Article
- EPR Effect-Based Tumor Targeted Nanomedicine: A Promising Approach for Controlling Cancer.Journal of personalized medicine · 2022Article
- Smart Lipid-Based Nanosystems for Therapeutic Immune Induction against Cancers: Perspectives and Outlooks.Pharmaceutics · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
For more than three decades, enhanced permeability and retention (EPR)-effect-based nanomedicines have received considerable attention for tumor-selective treatment of solid tumors. However, treatment of advanced cancers remains a huge challenge in clinical situations because of occluded or embolized tumor blood vessels, which lead to so-called heterogeneity of the EPR effect. We previously developed a method to restore impaired blood flow in blood vessels by using nitric oxide donors and other agents called EPR-effect enhancers. Here, we show that two novel EPR-effect enhancers-isosorbide dinitrate (ISDN, Nitrol
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.